LAM-话题@MedSci

#LAM#

157篇内容 | 4025人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2057683, encodeId=bbc2205e68378, content=<a href='/topic/show?id=c02b106e29a' target=_blank style='color:#2F92EE;'>#LAM#</a>, objectTitle=Immun Inflamm Dis：舌下免疫治疗后鼻拭子中异染性细胞数量减少 , objectType=article, longId=195967, objectId=43ae19596ebe, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=43ae19596ebe, replyNumber=0, likeNumber=66, createdTime=2021-02-17, rootId=0, userName=lxg951, userId=04ce158, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=43ae19596ebe, moduleTitle=Immun Inflamm Dis：舌下免疫治疗后鼻拭子中异染性细胞数量减少 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=43ae19596ebe)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2057670, encodeId=96e5205e67027, content=<a href='/topic/show?id=c02b106e29a' target=_blank style='color:#2F92EE;'>#LAM#</a>, objectTitle=Alnylam的第二款RNAi药物Givlaari，获得欧盟批准治疗肝卟啉症, objectType=article, longId=189441, objectId=02d9189441ee, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=02d9189441ee, replyNumber=0, likeNumber=67, createdTime=2020-04-21, rootId=0, userName=lxg951, userId=04ce158, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=02d9189441ee, moduleTitle=Alnylam的第二款RNAi药物Givlaari，获得欧盟批准治疗肝卟啉症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=02d9189441ee)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2057669, encodeId=dad5205e669d2, content=<a href='/topic/show?id=c02b106e29a' target=_blank style='color:#2F92EE;'>#LAM#</a>, objectTitle=RNAi治疗COVID-19：Alnylam与Vir Biotechnology联手开发, objectType=article, longId=189413, objectId=9aac1894137a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9aac1894137a, replyNumber=0, likeNumber=48, createdTime=2020-06-14, rootId=0, userName=lxg951, userId=04ce158, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9aac1894137a, moduleTitle=RNAi治疗COVID-19：Alnylam与Vir Biotechnology联手开发, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9aac1894137a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2057675, encodeId=42ec205e675f5, content=<a href='/topic/show?id=c02b106e29a' target=_blank style='color:#2F92EE;'>#LAM#</a>, objectTitle=Alnylam/Vir宣布推进RNAi疗法VIR-2703，用于抵抗新冠病毒COVID-19, objectType=article, longId=193613, objectId=b78f193613fa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b78f193613fa, replyNumber=0, likeNumber=74, createdTime=2020-06-21, rootId=0, userName=lxg951, userId=04ce158, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b78f193613fa, moduleTitle=Alnylam/Vir宣布推进RNAi疗法VIR-2703，用于抵抗新冠病毒COVID-19, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b78f193613fa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2057684, encodeId=d06b205e68477, content=<a href='/topic/show?id=c02b106e29a' target=_blank style='color:#2F92EE;'>#LAM#</a>, objectTitle=Inflamm Res：IL18, FOXP3和IL13基因多态性和过敏性鼻炎风险相关性分析 , objectType=article, longId=196184, objectId=afe21961845d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=afe21961845d, replyNumber=0, likeNumber=64, createdTime=2021-05-11, rootId=0, userName=lxg951, userId=04ce158, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=afe21961845d, moduleTitle=Inflamm Res：IL18, FOXP3和IL13基因多态性和过敏性鼻炎风险相关性分析 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=afe21961845d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2057671, encodeId=0df8205e671e8, content=<a href='/topic/show?id=c02b106e29a' target=_blank style='color:#2F92EE;'>#LAM#</a>, objectTitle=J Neuroinflammation：急性缺血性脑卒中患者的HLA和杀伤细胞免疫球蛋白样受体（KIRs）基因分型, objectType=article, longId=191605, objectId=c73c191605ff, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c73c191605ff, replyNumber=0, likeNumber=77, createdTime=2021-02-23, rootId=0, userName=lxg951, userId=04ce158, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c73c191605ff, moduleTitle=J Neuroinflammation：急性缺血性脑卒中患者的HLA和杀伤细胞免疫球蛋白样受体（KIRs）基因分型, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c73c191605ff)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2057673, encodeId=bd59205e67367, content=<a href='/topic/show?id=c02b106e29a' target=_blank style='color:#2F92EE;'>#LAM#</a>, objectTitle=Radiother Oncol：中风险和高风险前列腺癌多中心II期hypo-FLAME试验的主要终点分析 , objectType=article, longId=192082, objectId=2ce019208213, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2ce019208213, replyNumber=0, likeNumber=75, createdTime=2020-05-20, rootId=0, userName=lxg951, userId=04ce158, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2ce019208213, moduleTitle=Radiother Oncol：中风险和高风险前列腺癌多中心II期hypo-FLAME试验的主要终点分析 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2ce019208213)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2057668, encodeId=447b205e66890, content=<a href='/topic/show?id=c02b106e29a' target=_blank style='color:#2F92EE;'>#LAM#</a>, objectTitle=脊髓性肌萎缩症（SMA）：SMN2剪接修饰剂risdiplam显示出明显作用, objectType=article, longId=187658, objectId=7b6118e65800, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7b6118e65800, replyNumber=0, likeNumber=69, createdTime=2020-11-20, rootId=0, userName=lxg951, userId=04ce158, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7b6118e65800, moduleTitle=脊髓性肌萎缩症（SMA）：SMN2剪接修饰剂risdiplam显示出明显作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7b6118e65800)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2057674, encodeId=4457205e674d7, content=<a href='/topic/show?id=c02b106e29a' target=_blank style='color:#2F92EE;'>#LAM#</a>, objectTitle=Alnylam的RNAi疗法Vutrisiran获得FDA快速通道指定，治疗hATTR淀粉样变性, objectType=article, longId=192376, objectId=8eeb1923e6a6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8eeb1923e6a6, replyNumber=0, likeNumber=121, createdTime=2020-10-19, rootId=0, userName=lxg951, userId=04ce158, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8eeb1923e6a6, moduleTitle=Alnylam的RNAi疗法Vutrisiran获得FDA快速通道指定，治疗hATTR淀粉样变性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8eeb1923e6a6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2057665, encodeId=f2a1205e665b1, content=<a href='/topic/show?id=c02b106e29a' target=_blank style='color:#2F92EE;'>#LAM#</a>, objectTitle=J Dent Res：Notch通过调节Lamin A协调牙周膜成熟, objectType=article, longId=178802, objectId=7c8f1e88027c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7c8f1e88027c, replyNumber=0, likeNumber=66, createdTime=2020-01-06, rootId=0, userName=lxg951, userId=04ce158, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7c8f1e88027c, moduleTitle=J Dent Res：Notch通过调节Lamin A协调牙周膜成熟, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7c8f1e88027c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2057666, encodeId=6ec8205e66680, content=<a href='/topic/show?id=c02b106e29a' target=_blank style='color:#2F92EE;'>#LAM#</a>, objectTitle=FDA批准Alnylam的RNAi疗法givosiran治疗罕见遗传病——急性肝卟啉症, objectType=article, longId=183486, objectId=889518348636, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=889518348636, replyNumber=0, likeNumber=87, createdTime=2020-08-14, rootId=0, userName=lxg951, userId=04ce158, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=889518348636, moduleTitle=FDA批准Alnylam的RNAi疗法givosiran治疗罕见遗传病——急性肝卟啉症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=889518348636)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2057667, encodeId=75a2205e667d1, content=<a href='/topic/show?id=c02b106e29a' target=_blank style='color:#2F92EE;'>#LAM#</a>, objectTitle=Alnylam的RNA干扰药物Givlaari作为欧盟首例治疗急性肝卟啉症的药物，获得了CHMP的积极评价, objectType=article, longId=187288, objectId=72c718e28817, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=72c718e28817, replyNumber=0, likeNumber=100, createdTime=2020-03-21, rootId=0, userName=lxg951, userId=04ce158, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=72c718e28817, moduleTitle=Alnylam的RNA干扰药物Givlaari作为欧盟首例治疗急性肝卟啉症的药物，获得了CHMP的积极评价, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=72c718e28817)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2057661, encodeId=6b66205e66152, content=<a href='/topic/show?id=c02b106e29a' target=_blank style='color:#2F92EE;'>#LAM#</a>, objectTitle=IJC：LAM患者cfDNA中驱动基因和体细胞突变的研究：可能为诊治提供有效的分子标志物及治疗靶点？, objectType=article, longId=174550, objectId=cad11e45500f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cad11e45500f, replyNumber=0, likeNumber=69, createdTime=2020-05-02, rootId=0, userName=lxg951, userId=04ce158, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cad11e45500f, moduleTitle=IJC：LAM患者cfDNA中驱动基因和体细胞突变的研究：可能为诊治提供有效的分子标志物及治疗靶点？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cad11e45500f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2057663, encodeId=74e7205e66301, content=<a href='/topic/show?id=c02b106e29a' target=_blank style='color:#2F92EE;'>#LAM#</a>, objectTitle=英国NICE批准Alnylam的基因干扰药物Onpattro用于治疗hATTR淀粉样变性, objectType=article, longId=175117, objectId=a1811e511786, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a1811e511786, replyNumber=0, likeNumber=61, createdTime=2020-03-31, rootId=0, userName=lxg951, userId=04ce158, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a1811e511786, moduleTitle=英国NICE批准Alnylam的基因干扰药物Onpattro用于治疗hATTR淀粉样变性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a1811e511786)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2057657, encodeId=4fd5205e65701, content=<a href='/topic/show?id=c02b106e29a' target=_blank style='color:#2F92EE;'>#LAM#</a>, objectTitle=AGING CELL：核膜蛋白lamin B1与胸腺衰老的关系, objectType=article, longId=164192, objectId=a72216419277, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a72216419277, replyNumber=0, likeNumber=76, createdTime=2019-11-08, rootId=0, userName=柳叶一刀, userId=778d36, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a72216419277, moduleTitle=AGING CELL：核膜蛋白lamin B1与胸腺衰老的关系, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a72216419277)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2057659, encodeId=82b9205e6598c, content=<a href='/topic/show?id=c02b106e29a' target=_blank style='color:#2F92EE;'>#LAM#</a>, objectTitle=JACC:LAMPOON术预防经导管二尖瓣置换术后左室流出道梗阻安全有效, objectType=article, longId=166942, objectId=7ceb1669423a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7ceb1669423a, replyNumber=0, likeNumber=117, createdTime=2019-10-06, rootId=0, userName=柳叶一刀, userId=778d36, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7ceb1669423a, moduleTitle=JACC:LAMPOON术预防经导管二尖瓣置换术后左室流出道梗阻安全有效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7ceb1669423a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2057647, encodeId=61b1205e6475c, content=<a href='/topic/show?id=c02b106e29a' target=_blank style='color:#2F92EE;'>#LAM#</a>, objectTitle=Inflam Bowel Dis：主动优化英夫利昔单抗单药治疗可以提高IBD治疗效果, objectType=article, longId=157178, objectId=612e15e17888, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=612e15e17888, replyNumber=0, likeNumber=55, createdTime=2019-03-26, rootId=0, userName=lxg951, userId=04ce158, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=612e15e17888, moduleTitle=Inflam Bowel Dis：主动优化英夫利昔单抗单药治疗可以提高IBD治疗效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=612e15e17888)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2057650, encodeId=7cdb205e6505a, content=<a href='/topic/show?id=c02b106e29a' target=_blank style='color:#2F92EE;'>#LAM#</a>, objectTitle=Inflam Bowel Dis： Golimumab的连续临床反应与重度溃疡性结肠炎患者病程变化相关, objectType=article, longId=157181, objectId=341f15e18134, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=341f15e18134, replyNumber=0, likeNumber=72, createdTime=2019-03-15, rootId=0, userName=柳叶一刀, userId=778d36, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=341f15e18134, moduleTitle=Inflam Bowel Dis： Golimumab的连续临床反应与重度溃疡性结肠炎患者病程变化相关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=341f15e18134)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2057662, encodeId=933c205e6623a, content=<a href='/topic/show?id=c02b106e29a' target=_blank style='color:#2F92EE;'>#LAM#</a>, objectTitle=Blood：SLAMF7high 单核细胞增多可作为埃罗妥珠单抗治疗JAK2V617F(+)骨髓纤维化患者的治疗靶点, objectType=article, longId=174843, objectId=33b11e4843cb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=33b11e4843cb, replyNumber=0, likeNumber=83, createdTime=2019-11-04, rootId=0, userName=lxg951, userId=04ce158, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=33b11e4843cb, moduleTitle=Blood：SLAMF7high 单核细胞增多可作为埃罗妥珠单抗治疗JAK2V617F(+)骨髓纤维化患者的治疗靶点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=33b11e4843cb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2057648, encodeId=78ca205e64826, content=<a href='/topic/show?id=c02b106e29a' target=_blank style='color:#2F92EE;'>#LAM#</a>, objectTitle=Inflam Bowel Dis：硫代嘌呤代谢物监测对小儿IBD患者硫嘌呤单药治疗耐久性的影响, objectType=article, longId=157179, objectId=ac0415e179cd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ac0415e179cd, replyNumber=0, likeNumber=71, createdTime=2019-02-20, rootId=0, userName=lxg951, userId=04ce158, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ac0415e179cd, moduleTitle=Inflam Bowel Dis：硫代嘌呤代谢物监测对小儿IBD患者硫嘌呤单药治疗耐久性的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ac0415e179cd)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

LAM

2020-05-29

lxg951 (审核中...)

前往app查看评论内容

#LAM#

Immun Inflamm Dis：舌下免疫治疗后鼻拭子中异染性细胞数量减少

2021-02-17

lxg951 (审核中...)

前往app查看评论内容

#LAM#

Alnylam的第二款RNAi药物Givlaari，获得欧盟批准治疗肝卟啉症

2020-04-21

lxg951 (审核中...)

前往app查看评论内容

#LAM#

RNAi治疗COVID-19：Alnylam与Vir Biotechnology联手开发

2020-06-14

lxg951 (审核中...)

前往app查看评论内容

#LAM#

Alnylam/Vir宣布推进RNAi疗法VIR-2703，用于抵抗新冠病毒COVID-19

2020-06-21

lxg951 (审核中...)

前往app查看评论内容

#LAM#

Inflamm Res：IL18, FOXP3和IL13基因多态性和过敏性鼻炎风险相关性分析

2021-05-11

lxg951 (审核中...)

前往app查看评论内容

#LAM#

J Neuroinflammation：急性缺血性脑卒中患者的HLA和杀伤细胞免疫球蛋白样受体（KIRs）基因分型

2021-02-23

lxg951 (审核中...)

前往app查看评论内容

#LAM#

Radiother Oncol：中风险和高风险前列腺癌多中心II期hypo-FLAME试验的主要终点分析

2020-05-20

lxg951 (审核中...)

前往app查看评论内容

#LAM#

脊髓性肌萎缩症（SMA）：SMN2剪接修饰剂risdiplam显示出明显作用

2020-11-20

lxg951 (审核中...)

前往app查看评论内容

#LAM#

Alnylam的RNAi疗法Vutrisiran获得FDA快速通道指定，治疗hATTR淀粉样变性

2020-10-19

lxg951 (审核中...)

前往app查看评论内容

#LAM#

J Dent Res：Notch通过调节Lamin A协调牙周膜成熟

2020-01-06

lxg951 (审核中...)

前往app查看评论内容

#LAM#

FDA批准Alnylam的RNAi疗法givosiran治疗罕见遗传病——急性肝卟啉症

2020-08-14

lxg951 (审核中...)

前往app查看评论内容

#LAM#

Alnylam的RNA干扰药物Givlaari作为欧盟首例治疗急性肝卟啉症的药物，获得了CHMP的积极评价

2020-03-21

lxg951 (审核中...)

前往app查看评论内容

#LAM#

IJC：LAM患者cfDNA中驱动基因和体细胞突变的研究：可能为诊治提供有效的分子标志物及治疗靶点？

2020-05-02

lxg951 (审核中...)

前往app查看评论内容

#LAM#

英国NICE批准Alnylam的基因干扰药物Onpattro用于治疗hATTR淀粉样变性

2020-03-31

柳叶一刀 (审核中...)

前往app查看评论内容

#LAM#

AGING CELL：核膜蛋白lamin B1与胸腺衰老的关系

2019-11-08

柳叶一刀 (审核中...)

前往app查看评论内容

#LAM#

JACC:LAMPOON术预防经导管二尖瓣置换术后左室流出道梗阻安全有效

2019-10-06

lxg951 (审核中...)

前往app查看评论内容

#LAM#

Inflam Bowel Dis：主动优化英夫利昔单抗单药治疗可以提高IBD治疗效果

2019-03-26

柳叶一刀 (审核中...)

前往app查看评论内容

#LAM#

Inflam Bowel Dis： Golimumab的连续临床反应与重度溃疡性结肠炎患者病程变化相关

2019-03-15

lxg951 (审核中...)

前往app查看评论内容

#LAM#

Blood：SLAMF7high 单核细胞增多可作为埃罗妥珠单抗治疗JAK2V617F(+)骨髓纤维化患者的治疗靶点

2019-11-04

lxg951 (审核中...)

前往app查看评论内容

#LAM#

Inflam Bowel Dis：硫代嘌呤代谢物监测对小儿IBD患者硫嘌呤单药治疗耐久性的影响

2019-02-20

科室
- - 订阅+
  - 更多科室
工具
服务